Every clinical trial relies on data from its study participants to inform decisions regarding the safety and efficacy of a potential new treatment. Clinical trial sponsors rely on the data from laboratory tests to bring clear insights that advance studies. Labcorp Central Laboratory Services generates more clinical trial data than …
Faster access to biopesticide alternatives to conventional pesticides under the U.S. BPPD regulatory framework
There is pressure worldwide for better, faster access to biological alternatives to conventional crop protection chemicals (CPCs). The U.S. Environmental Protection Agency (EPA) is ahead of regions such as the European Union (EU) in revising its regulatory approaches for biopesticides and in having a division dedicated to them, namely, the …
Alcohol-related liver disease: Inherent Challenges and Strategies for Successful Clinical Trial Conduct
The association between excessive alcohol consumption and liver disease is well documented. In fact, the effect on alcohol consumption levels during the COVID-19 pandemic has more recently been investigated. In a 2022 Hepatology article, researchers estimated that the one-year increase in alcohol consumption during the pandemic would result in an …
Program management services are now offered as part of Labcorp’s Preclinical Oncology Services
When it comes to discoveries in oncology, cancer patients can’t wait, which means neither can you. At Labcorp Preclinical Oncology, we understand there are many steps, phases and regulations to wade through to get to a lead drug candidate—all while time is of the utmost importance. We are excited to …
Enabling better access to kidney disease trials
March is National Kidney Month, and we at Labcorp are committed to improving the renal health of patients worldwide. The field of nephrology clinical research has been steadily adding new interventional trials over the last five years at an average pace of 176 trials per year. This activity reflects the …
Innovative collaboration between Biomakers and Labcorp to provide greater access to oncology patients in Latin America
In December 2022, Labcorp and Biomakers signed an agreement that will positively impact thousands of cancer patients in Latin America through greater access to diagnostic molecular profiling and participation in clinical trials. We recently asked Nicolas Kirchuk (NK), CEO and co-founder of Biomakers, and Isagani Chico (IC), MD, VP, global …
Delivering solutions to the next generation of cardiovascular medicines
JB Flinders, Senior Director, CVMER, Operational Strategy and Planning and Peter Alfinito, Executive Director, CVMER, Operational Strategy and Planning February is American Heart Month, and we at Labcorp are dedicated to improve the cardiovascular health of patients worldwide, as part of Labcorp’s mission to improve health and improve lives. This …
Improving access to rare disease trials by incorporating DCT elements
Welcome to the February 2023 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. With Rare Disease Day coming soon on February 28, we are going to focus on how patients, sites and investigators can benefit by improving the design and execution of rare disease trials. What is Rare Disease Day? …
4 emerging trends to watch in immunotherapy clinical trials
Approaches to systemic anticancer therapy have shifted in recent decades. The nonspecific cytotoxic agents that once dominated the oncotherapy space first gave way to more targeted agents in the 1980s and 1990s, after which advanced, novel immunotherapeutic strategies took center stage. The potential of such immunotherapies to address untreatable malignancies …
What the latest changes to EU regulations and data requirements mean for your microbial biopesticide registrations and renewals
Despite perceptions that biopesticides are inherently less dangerous, the EU regulates them as stringently as conventional, potentially highly hazardous, synthetic plant protection chemicals (Regulation [EC] No. 1107/2009). This has made approvals costly and slow. Recent regulatory revisions intended to redress this—to give EU farmers better and faster access to biological …